LivaNova (NASDAQ:LIVN) Upgraded to “Buy” by StockNews.com

StockNews.com upgraded shares of LivaNova (NASDAQ:LIVN) from a hold rating to a buy rating in a research report released on Thursday.

A number of other research firms also recently commented on LIVN. Mizuho reissued a buy rating and issued a $75.00 target price on shares of LivaNova in a report on Wednesday, March 27th. Barclays raised their target price on LivaNova from $57.00 to $61.00 and gave the company an equal weight rating in a report on Monday, February 26th. Needham & Company LLC reaffirmed a buy rating and set a $72.00 price target on shares of LivaNova in a research note on Wednesday, March 20th. Finally, Robert W. Baird lifted their price target on LivaNova from $56.00 to $62.00 and gave the stock a neutral rating in a research note on Thursday, February 22nd. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of Moderate Buy and an average price target of $64.40.

LivaNova Stock Performance

NASDAQ:LIVN opened at $55.10 on Thursday. The firm’s fifty day moving average price is $54.02 and its 200 day moving average price is $50.62. LivaNova has a 1-year low of $42.75 and a 1-year high of $59.86. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.95 and a quick ratio of 2.51. The firm has a market cap of $2.97 billion, a price-to-earnings ratio of 172.19 and a beta of 0.89.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, February 21st. The company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.10. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The firm had revenue of $310.10 million for the quarter, compared to analyst estimates of $287.65 million. During the same period last year, the firm posted $0.81 EPS. LivaNova’s quarterly revenue was up 12.8% on a year-over-year basis. On average, sell-side analysts expect that LivaNova will post 3.01 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in LIVN. Norges Bank acquired a new position in LivaNova in the 4th quarter valued at about $26,064,000. Ameriprise Financial Inc. grew its holdings in LivaNova by 96.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 916,632 shares of the company’s stock valued at $48,471,000 after buying an additional 449,136 shares during the period. Primecap Management Co. CA grew its holdings in LivaNova by 7.3% in the 3rd quarter. Primecap Management Co. CA now owns 5,785,360 shares of the company’s stock valued at $305,930,000 after buying an additional 395,940 shares during the period. Loomis Sayles & Co. L P grew its holdings in LivaNova by 31.1% in the 3rd quarter. Loomis Sayles & Co. L P now owns 879,740 shares of the company’s stock valued at $46,520,000 after buying an additional 208,755 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in LivaNova in the 4th quarter valued at about $8,330,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.